Michael Hays, President, Integreon Global
Advertisement
Articles by Michael Hays, President, Integreon Global
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
MFN Is an Offer Pharma Can’t Refuse
4
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
5